Ola Flink
Director/Board Member bij LIPIDOR AB
Profiel
Ola Flink is currently the Chairman of Dr. Flink Consulting AB and the Director of Eribis Pharmaceuticals AB, Lipidor AB, and.
Biocelex Ltd.
Oy.
Previously, he served as the Chairman & Chief Executive Officer of OncoReg AB from 2010 to 2012.
He was also the Chairman of KDev Exploratory AB, BioChromix Pharma AB, Calabar International AB, and Calabar AB.
Additionally, he held director positions at Oncopeptides AB, BioCis Pharma Oy, Biosergen AS, Axelar AB, Asarina Pharma AB, Umecrine Cognition AB, Akinion Pharmaceuticals AB, and MarBiLeads AS.
From 2008 to 2013, Dr. Flink worked as an Investment Manager at Karolinska Development AB (Private Equity) and later became the Vice President-Portfolio Management at Karolinska Development AB.
Actieve functies van Ola Flink
Bedrijven | Functie | Begin |
---|---|---|
LIPIDOR AB | Director/Board Member | 01-01-2020 |
Biocelex Ltd. Oy | Director/Board Member | 21-04-2011 |
Eribis Pharmaceuticals AB
Eribis Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Eribis Pharmaceuticals AB, ('Eribis') was founded by Erik Bissessar and co-founded by Herman Krapf. Karolinska Development is the primary investing partner. The basis of Eribis is the Company's unique competence in developing peptides for the pharmacological use for treatment of several clinical indications. The company's main focus is on developing new, effective and safe drugs for the treatment of cardiovascular disorders, in particular acute myocardial ischemia, and also for surgical preconditioning. The Company is based on research in the fields of peptide chemistry and pharmacology. The main goal for Eribis is to develop its Candidate Drug to meet the market's demand for new and improved treatment in the field of cardio-protection. Other medical indications may be considered at a later stage. | Director/Board Member | - |
Ola Flink Consulting AB | Chairman | - |
Eerdere bekende functies van Ola Flink
Bedrijven | Functie | Einde |
---|---|---|
BioCis Pharma Oy
BioCis Pharma Oy Pharmaceuticals: MajorHealth Technology BioCis Pharma is a clinical stage drug development company with the business idea to design and develop novel pharmaceutical products based on its proprietary technology platform. BioCis Pharma is targeting unmet medical needs in substantial therapeutic markets including inflammation, allergy, and cancer. The first products are being developed for major medical indications in dermatology, ophthalmology, and urology. BioCis Pharma was founded in 2003 by Dr. Lasse Leino and Dr. Jarmo Laihia, two experienced research and development professionals with both industrial and scientific backgrounds. Since the start of its operation in December 2004, BioCis Pharma has shown exceptional ability to move product candidates forward in development programs, having now two high-potential products under clinical Phase I-II development. | Director/Board Member | 01-05-2014 |
Calabar International AB
Calabar International AB Pharmaceuticals: MajorHealth Technology Calabar International AB develops novel locally administered formulations against dry mouth with the acetyl cholinesterase inhibitor physostigmine as the active substance. The flow of saliva produced by the minor glands is increased by preventing the breakdown of acetylcholine. The company is headquartered in Billdal, Sweden. | Chairman | 03-01-2014 |
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Private Equity Investor | 31-12-2013 |
OncoReg AB
OncoReg AB Medical SpecialtiesHealth Technology OncoReg's business concept is to provide novel sensitizers that enhance the sensitivity of tumors to other treatments. OncoReg has found that a combination of radiotherapy and its sensitizer can make therapy resistant tumors responsive to radiotherapy. The firm's lead compound, in combination with radiotherapy, leads to total regression of therapy resistant tumors in mice. | Chairman | 20-01-2012 |
Axelar AB
Axelar AB BiotechnologyHealth Technology Axelar AB operates as a biotechnology company. It aims to develop novel efficacious anti-cancer treatments. The company was founded by Erik Gustav Magnus Axelson and Lars Olov Larsson in 2003 and is headquartered in Solna, Sweden. | Director/Board Member | 03-06-2010 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 4 |
---|---|
ONCOPEPTIDES AB | Health Technology |
LIPIDOR AB | Commercial Services |
ASARINA PHARMA AB | Health Technology |
KAROLINSKA DEVELOPMENT AB | Finance |
Bedrijven in privébezit | 15 |
---|---|
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Finance |
BioCis Pharma Oy
BioCis Pharma Oy Pharmaceuticals: MajorHealth Technology BioCis Pharma is a clinical stage drug development company with the business idea to design and develop novel pharmaceutical products based on its proprietary technology platform. BioCis Pharma is targeting unmet medical needs in substantial therapeutic markets including inflammation, allergy, and cancer. The first products are being developed for major medical indications in dermatology, ophthalmology, and urology. BioCis Pharma was founded in 2003 by Dr. Lasse Leino and Dr. Jarmo Laihia, two experienced research and development professionals with both industrial and scientific backgrounds. Since the start of its operation in December 2004, BioCis Pharma has shown exceptional ability to move product candidates forward in development programs, having now two high-potential products under clinical Phase I-II development. | Health Technology |
KDev Exploratory AB
KDev Exploratory AB Miscellaneous Commercial ServicesCommercial Services KDev Exploratory AB provides drug discovery solutions. It performs discovery research in various therapeutic areas, such as screening in oncology, neuroscience, lead finding, characterization in inflammation and angiogenesis/age-related macular degeneration. The company was founded by David Jern in 2000 and is headquartered in Solna, Sweden. | Commercial Services |
Biosergen AS
Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Health Technology |
Axelar AB
Axelar AB BiotechnologyHealth Technology Axelar AB operates as a biotechnology company. It aims to develop novel efficacious anti-cancer treatments. The company was founded by Erik Gustav Magnus Axelson and Lars Olov Larsson in 2003 and is headquartered in Solna, Sweden. | Health Technology |
Calabar AB
Calabar AB Medical SpecialtiesHealth Technology Calabar AB is a privately-held company committed to developing a pharmaceutical product addressing the great unmet needs of xerostomia, dry mouth. The company develops XALIEVE™ a locally administered formulation of the cholinesterase inhibitor physostigmine, which been shown to effectively increase salivary flow. Unlike systemically administered drugs, the local route of administration significantly limits adverse events. The compound is currently undergoing Phase II repeated dose studies and Calabar is actively looking for partners to take the compound through phase III. For more information contact Business Development. The company is part of the Karolinska Development AB (publ) portfolio. | Health Technology |
Eribis Pharmaceuticals AB
Eribis Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Eribis Pharmaceuticals AB, ('Eribis') was founded by Erik Bissessar and co-founded by Herman Krapf. Karolinska Development is the primary investing partner. The basis of Eribis is the Company's unique competence in developing peptides for the pharmacological use for treatment of several clinical indications. The company's main focus is on developing new, effective and safe drugs for the treatment of cardiovascular disorders, in particular acute myocardial ischemia, and also for surgical preconditioning. The Company is based on research in the fields of peptide chemistry and pharmacology. The main goal for Eribis is to develop its Candidate Drug to meet the market's demand for new and improved treatment in the field of cardio-protection. Other medical indications may be considered at a later stage. | Health Technology |
OncoReg AB
OncoReg AB Medical SpecialtiesHealth Technology OncoReg's business concept is to provide novel sensitizers that enhance the sensitivity of tumors to other treatments. OncoReg has found that a combination of radiotherapy and its sensitizer can make therapy resistant tumors responsive to radiotherapy. The firm's lead compound, in combination with radiotherapy, leads to total regression of therapy resistant tumors in mice. | Health Technology |
BioChromix Pharma AB
BioChromix Pharma AB Miscellaneous Commercial ServicesCommercial Services BioChromix Pharma AB was founded as a subsidiary to BioChromix AB. The Company is a pharmaceutical company active in research and development of novel treatments for neurodegenerative disorders based on its proprietary technology for therapeutics. Current research and development is focused on the indication area of Alzheimer's disease but the prion diseases, Parkinson's disease and other neurodegenerative disorders might also be included in the future. BioChromix Pharma is performing pre-clinical development but is looking to reach the clinical phase within the coming years. Alzheimer's disease is the most common neurodegenerative disease, affecting around 25 million people and the costs associated with AD are tremendous. At the moment, there are no efficient treatments for AD but there are clinical trials are ongoing and some are focused at reducing the levels of the neurotoxic Aß peptide. The portfolio of the company includes a number of newly discovered lead compounds that are under investigation. | Commercial Services |
Umecrine Cognition AB
Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | Health Technology |
Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Health Technology |
Biocelex Ltd. Oy | |
Calabar International AB
Calabar International AB Pharmaceuticals: MajorHealth Technology Calabar International AB develops novel locally administered formulations against dry mouth with the acetyl cholinesterase inhibitor physostigmine as the active substance. The flow of saliva produced by the minor glands is increased by preventing the breakdown of acetylcholine. The company is headquartered in Billdal, Sweden. | Health Technology |
MarBiLeads AS
MarBiLeads AS BiotechnologyHealth Technology MarBiLeads AS engages in the development of drug candidates for infections and cancer based on marine microorganisms. The company was founded on December 22, 2010 and is headquartered in Trondheim, Norway. | Health Technology |
Ola Flink Consulting AB |